PMID- 32062314
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20200408
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 148
DP  - 2020 Apr
TI  - The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven 
      non small cell lung cancer: State of the art.
PG  - 102894
LID - S1040-8428(20)30032-9 [pii]
LID - 10.1016/j.critrevonc.2020.102894 [doi]
AB  - Oncogene-driven non small cell lung cancer (NSCLC) is a distinct entity in 
      thoracic oncology. The availability of effective target therapies, like EGFR 
      inhibitors or ALK inhibitors, have revolutionized the prognosis of these 
      patients. However, despite an initial response in the majority of patients, drug 
      resistance ultimately occurs. In some cases, this resistance develops in few 
      clonal cells (oligoprogression), so that a local ablation of these resistant 
      deposits could allow to maintain the same systemic therapy and possibly to 
      prolong patients' survival. For these purposes, stereotactic body radiation 
      therapy (SBRT) is an ideal local ablative treatment, because it is effective, non 
      invasive and with limited side effects. In this review, we aim to analyze 
      available clinical data to verify whether SBRT can allow these patients to 
      continue with existing target therapy longer, delay the switch to other systemic 
      therapies and improve their outcome modifying the natural history of the disease.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Franceschini, D
AU  - Franceschini D
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Centre, 
      Rozzano, Milan, Italy. Electronic address: davide.franceschini@humanitas.it.
FAU - De Rose, F
AU  - De Rose F
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Centre, 
      Rozzano, Milan, Italy.
FAU - Cozzi, S
AU  - Cozzi S
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Centre, 
      Rozzano, Milan, Italy.
FAU - Franzese, C
AU  - Franzese C
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Centre, 
      Rozzano, Milan, Italy.
FAU - Rossi, S
AU  - Rossi S
AD  - Department of Oncology and Hematology, Humanitas Clinical and Research Center, 
      Rozzano, Milan, Italy.
FAU - Finocchiaro, G
AU  - Finocchiaro G
AD  - Department of Oncology and Hematology, Humanitas Clinical and Research Center, 
      Rozzano, Milan, Italy.
FAU - Toschi, L
AU  - Toschi L
AD  - Department of Oncology and Hematology, Humanitas Clinical and Research Center, 
      Rozzano, Milan, Italy.
FAU - Santoro, A
AU  - Santoro A
AD  - Department of Oncology and Hematology, Humanitas Clinical and Research Center, 
      Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, 
      Rozzano, Milano, Italy.
FAU - Scorsetti, M
AU  - Scorsetti M
AD  - Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Centre, 
      Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, 
      Rozzano, Milano, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200205
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/pathology/*radiotherapy
MH  - Catheter Ablation
MH  - Disease Progression
MH  - Humans
MH  - Lung Neoplasms/pathology/*radiotherapy
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - Oncogenes
MH  - Protein Kinase Inhibitors
MH  - *Radiosurgery
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Lung cancer
OT  - Oligopersistence
OT  - Oligoprogression
OT  - Oncogene-driven
OT  - Radiotherapy
EDAT- 2020/02/18 06:00
MHDA- 2020/04/09 06:00
CRDT- 2020/02/17 06:00
PHST- 2019/07/22 00:00 [received]
PHST- 2020/01/14 00:00 [revised]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2020/02/18 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2020/02/17 06:00 [entrez]
AID - S1040-8428(20)30032-9 [pii]
AID - 10.1016/j.critrevonc.2020.102894 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2020 Apr;148:102894. doi: 
      10.1016/j.critrevonc.2020.102894. Epub 2020 Feb 5.